Arcus Data Positions Casdatifan as Potential All-Line Backbone in Kidney Cancer, Mizuho Says
Fresh ARC-20 data from Arcus show strong PFS and OS for casdatifan in first-, second- and late-line clear cell kidney cancer, per Mizuho.
Already have an account? Sign in.